Back to Search
Start Over
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
- Source :
-
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2009 Jan; Vol. 63 (1), pp. 94-7. Date of Electronic Publication: 2008 May 16. - Publication Year :
- 2009
-
Abstract
- Malignant pleural mesothelioma (MPM) is a rapidly progressive invariably lethal tumor. Treatment options remain limited and the outcome in relapsed disease is poor warranting new therapeutic options. Following our previous experience in the first-line setting, we conducted a phase 2 open-label non-comparative study to assess the safety and efficacy of weekly vinorelbine chemotherapy, each cycle consisting of 30 mg/m(2) for 6 weeks, in patients with previous exposure to chemotherapy. In 63 individuals with relapsed MPM who had not received previous vinorelbine, we observed an objective response rate of 16% and an overall survival of 9.6 months (95% confidence interval 7.3-11.8 months). The main grade III/IV toxicity observed was neutropenia and toxicity was similar to weekly vinorelbine when used in the first-line setting. Weekly vinorelbine appeared to have a reasonable response rate with an acceptable toxicity profile in the second-line treatment of MPM. Its use should be prospectively evaluated in a randomised trial in the first or second-line therapy of MPM.
- Subjects :
- Adult
Aged
Disease Progression
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Recurrence
Time Factors
Treatment Outcome
Vinblastine administration & dosage
Vinorelbine
Antineoplastic Agents administration & dosage
Mesothelioma drug therapy
Mesothelioma pathology
Pleural Neoplasms drug therapy
Pleural Neoplasms pathology
Vinblastine analogs & derivatives
Subjects
Details
- Language :
- English
- ISSN :
- 0169-5002
- Volume :
- 63
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Lung cancer (Amsterdam, Netherlands)
- Publication Type :
- Academic Journal
- Accession number :
- 18486273
- Full Text :
- https://doi.org/10.1016/j.lungcan.2008.04.001